Medical devices, healthcare technology and the business of care
PMA SUPPLEMENT · P170030/S066

ORSIRO Sirolimus Eluting Coronary Stent System

Biotronik AG · Decision date Sep 24, 2026

MEDTECHLEDGER EXPLANATIONP170030/S066

What did the FDA decide?

The FDA recorded a 30-Day Notice decision, OK30, dated 2026-09-24, for the ORSIRO Sirolimus Eluting Coronary Stent System under application P170030/S066, submitted by Biotronik AG. The product is a coronary drug-eluting stent in the cardiovascular specialty, product code NIQ. The supplement type is a 30-Day Notice, and the recorded reason is a process change affecting manufacturer, sterilizer, packager or supplier.

The stated scope is changes to solvent preparation and drug coating application. This entry covers that manufacturing process change within the existing P170030 application; it is not a new approval of the whole stent system, and the source does not describe clinical data, coating specifications or the effect on finished-device performance. The source also does not include the decision documents, so the review basis behind OK30 remains unknown from this record.

FDA approval order statement

changes to solvent preparation and drug coating application
Regulatory pathway
PMA supplement
Supplement type
30-Day Notice
Clinical specialty
Cardiovascular
Decision date
Sep 24, 2026
FDA change category
Process Change - Manufacturer/Sterilizer/Packager/Supplier

FDA source record · MedtechLedger’s explanation describes the recorded change.

Regulatory record facts

Identifier
P170030/S066
Regulatory pathway
PMA supplement
Applicant
Biotronik AG
Product code
NIQ
Decision code
OK30
Decision date
Sep 24, 2026
Source update
Nov 9, 2026
Original record
Open FDA source record

About this medical device

FDA device category: Coronary drug-eluting stent.

Applicant
Biotronik AG
Product code
NIQ
FDA device class
3

For the original device and its historical approval scope, see PMA P170030. Subsequent supplements may change the device or its indications.

FDA decision timeline

  1. P170030 · Original PMA

    ORSIRO Sirolimus Eluting Coronary Stent System

  2. P170030/S066 received

    Application receipt date recorded by FDA.

  3. P170030/S066 · FDA decision

    30-Day Notice

Timeline entries are records held by MedtechLedger for P170030. View FDA’s full supplement list.

Related devices and submissions

Same PMA: P170030

Product / regulatory recordCompanyPathwayDecision dateSource
Biotronik AGPMA approvalFeb 22, 2019FDA

Explore the linked device profile

Other records with product code NIQ

A shared product code identifies a classification relationship; it does not establish clinical equivalence.

Regulatory context

A PMA supplement records a change to a device with an existing premarket approval. The supplement’s approval applies to the change described in that submission.

Read our guide to FDA clearance and approval · FDA’s explanation of this pathway

Manufacturer intelligence

Biotronik AG

Headquarters
Not reported
Brand website
Not reported
FDA applicant address
Ackerstrasse 6, Bülach, 8180

Sources and methodology

FDA fields and approval-order wording are presented as source information. MedtechLedger explanations are identified separately and describe the scope of the recorded decision. Indications from an original PMA are historical unless confirmed against subsequent labeling and supplements.

How we use FDA records